Opioid use disorder, along with injection drug use (IDU) and its associated complications, have developed into an urgent, nationwide public health crisis. Wounds and skin and soft tissue infections (SSTIs) are common complications of IDU that disproportionately affect people who inject drugs (PWID) and are a major source of morbidity and mortality for this population. More recently, there has been a steep increase reported in the prevalence of xylazine detected in post-mortem toxicology tests among fatal overdose victims and fentanyl screen-positive urine samples. The emergence of xylazine adds novel health risks. In addition to the manner in which it complicates risk for overdose, chronic use of xylazine can progress vasoconstriction and skin oxygenation deficit, leading to SSTIs, including abscesses, skin ulceration, and cellulitis. Such complications have been documented over various body parts irrespective of the injection site. Providing early wound care intervention can reduce morbidity and mortality and related health care costs by reducing the number of SSTIs and injection-related wounds that require hospital admission. This workshop will provide an opportunity to further your knowledge and experience regarding wound care intervention for persons who use drugs (PWUD). This includes an overview of best practices for screening and identifying wounds, as well as best practice recommendations for basic wound care intervention that could be administered by non-medically trained personnel in the context of routine outreach. Participants will have the opportunity to practice basic wound care intervention with certified wound care nurse specialists.